The selective 5-HT1A receptor antagonist WAY-100635 inhibits neuronal activity of the ventromedial prefrontal cortex in a rodent model of Parkinson's disease

Neuroscience Bulletin

Volumn 23, Issue 6, 2007, Pages 315-322

  Cao, Jian ^a,c   Liu, Jian ^a,b   Zhang, Qiao Jun ^a   Wang, Tao ^a   Wang, Shuang ^a   Han, Ling Na ^a   Li, Qiang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

5 HT1A receptor; Electrophysiology; Medial prefrontal cortex; Parkinson's disease; WAY 100635

Indexed keywords

N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; SEROTONIN 1A ANTAGONIST; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; EXPERIMENTAL MODEL; MALE; MICROELECTRODE; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; RAT; SUBSTANTIA NIGRA; ZONA COMPACTA; ACTION POTENTIAL; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; METABOLISM; NEOSTRIATUM; NERVE CELL; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACTION POTENTIALS; ANIMALS; DISEASE MODELS, ANIMAL; MALE; NEOSTRIATUM; NEURAL PATHWAYS; NEURONS; PARKINSON DISEASE; PIPERAZINES; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; SUBSTANTIA NIGRA;

EID: 38149056559     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-007-0047-5     Document Type: Article

References (38)

1. Miyawaki E, Meah Y, Koller WC. Serotonin, dopamine, and motor effects in Parkinson's disease. Clin Neuropharmacol 1997, 20: 300-310.
2. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noredrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983, 275: 321-328.
3. Fuster JM. The prefrontal cortex-an update: time is of the essence. Neuron 2001, 30: 319-333.
4. Brooks DJ, Piccini P. Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry 2006, 59: 908-918.
5. 1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001, 39: 288-296.
6. Dubois B, Pillon B. Do cognitive changes of Parkinson's disease result from dopamine depletion? J Neural Transm (Suppl) 1995, 45: 27-34.
7. 2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 2004, 14: 281-299.
8. 1A receptors. Neuropharmacology 2003, 45: 72-81.
9. Puig MV, Artigas F, Celada P. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex 2005, 15: 1-14.
10. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990, 510: 104-107.
11. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. In: Academic Press. California, USA, 1998.
12. Hassani OK, Feger J. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine- lesioned rats: an electrophysiological and c-Fos study. Neuroscience 1999, 92: 533-543.
13. Fedrowitz M, Lindemann S, Loscher W, Gernert M. Altered spontaneous discharge rate and pattern of basal ganglia output neurons in the circling (ci2) rat mutant. Neuroscience 2003, 118: 867-878.
14. Murer MG, Riquelme LA, Tseng KY, Pazo JH. Substantia nigra pars reticulata single unit activity in normal and 6-OHDA-lesioned rats: effects of intrastriatal apomorphine and subthalamic lesions. Synapse 1997, 27: 278-293.
15. Tierney PL, Degenetais E, Thierry AM, Glownski J, Gioanni Y. Influence of the hippocampus on interneurons of the rat prefrontal cortex. Eur J Neurosci 2004, 20: 514-524.
16. O'Hearn E, Molliver ME. Organization of raphe-cortical projections in rat: a quantitative retrograde study. Brain Res Bull 1984, 13: 709-726.
17. Thierry AM, Deniau JM, Feger J. Effects of stimulation of the frontal cortex on identified output VMT cells in the rat. Neurosci Lett 1979, 15: 102-107.
18. Pirot S, Godbout R, Mantz J, Tassin JP, Glowinski J, Thierry AM. Inhibitory effects of ventral tegmental area stimulation on the activity of prefrontal cortical neurons: evidence for the involvement of both dopaminergic and GABAergic components. Neuroscience 1992, 49: 857-865.
19. Seguela P, Watkins KC, Geffard M, Descarries L. Noradrenaline axon terminals in adult rat neocortex: an immunocytochemical analysis in serial thin sections. Neuroscience 1990, 35: 249-264.
20. Devoto P, Flore G, Saba P, Fa M, Gessa GL. Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus. BMC Neurosci 2005, 6: 31.
21. Kovacs P, Hernadi I. Alpha2 antagonist yohimbine suppresses maintained firing of rat prefrontal neurons in vivo. Neuroreport 2003, 14: 833-836.
22. Bertrand E, Lechowicz W, Szpak GM, Dymecki J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol 1997, 35: 80-86.
23. Dymecki J, Lechowicz W, Bertrand E, Szpak GM. Changes in dopaminergic neurons of the mesocorticolimbic system in Parkinson's disease. Folia Neuropathol 1996, 34: 102-106.
24. Tohgi H, Abe T, Takahashi S, Takahashi J, Hamato H. Concentration of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 1993, 150: 71-74.
25. 2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res 2005, 1045: 229-233.
26. Cash R, Ruberg M, Raisman R, Agid Y. Adrenergic receptors in Parkinson's disease. Brain Res 1984, 322: 269-275.
27. Ferron A, Thierry AM, Le Douarin C, Glowinski J. Inhibitory influence of the mesocortical dopaminergic system on spontaneous activity or excitatory response induced from the thalamic mediodorsal nucleus in the rat medial prefrontal cortex. Brain Res 1984, 302: 257-265.
28. Magnin M, Morel A, Jeanmonod D. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in Parkinsonian patients. Neuroscience 2000, 96: 549-564.
29. 1 receptor. Eur J Pharmacol 1988, 157: 173-181.
30. Hajos M, Allers KA, Jennings K, Sharp T, Charette G, Sík A, et al. Neurochemical identification of stereotypic burst-firing neurons in the rat dorsal raphe nucleus using juxtacellular labelling methods. Eur J Neurosci 2007, 25: 119-126.
31. 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004, 14: 1100-1109.
32. 1A receptor antagonist. Behav Brain Res 1996, 73: 337-353.
33. 1A receptors. Neurosci Lett 2001, 304: 129-132.
34. 1A autoreceptors in the rat dorsal raphe nucleus. Neuropsychopharmacology 2004, 29: 1800-1806.
35. 1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 1998, 30: 172-180.
36. Haddjeri N, de Montigny C, Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. Br J Pharmacol 1997, 120: 865-875.
37. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003, 60: 337-341.
38. 1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992, 12: 440-453.